Literature DB >> 24026983

Antiemetic prescribing practices using a computerized physician order entry system.

Kunal C Kadakia1, Alexis D Leal, Drew K Seisler, Rui Qin, Kelliann C Fee-Schroeder, Darryl C Grendahl, Kristine M Sorgatz, Charles L Loprinzi.   

Abstract

PURPOSE: Adherence to guideline-consistent chemotherapy-induced nausea and vomiting (CINV) prophylaxis is suboptimal. The primary aim of this study was to evaluate the magnitude of compliance to institutional guideline-directed antiemetic prophylaxis using a computerized physician order entry system at a single tertiary care institution. A nurse survey was also performed to evaluate how oncology practices, within a cooperative group, managed clinician orders for the prevention of CINV.
METHODS: The electronic medical records of 100 consecutive patients were evaluated. The primary endpoint was the incidence of compliance to provide all aspects of scheduled institutional guideline-directed antiemetic prophylaxis for acute (day 1) and delayed (days 2-4) CINV. A descriptive analysis was performed on the convenience sample. Logistic regression was completed to determine the predictors of noncompliance.
RESULTS: The incidence of compliance on days 1-4 was 94 %. Half of the noncompliant events (three of six, 50 %) occurred on day 1 alone and involved patients receiving low-emetogenic chemotherapy. There was a high degree of compliance to institutional guidelines for the treatment of delayed CINV (97 %). Patients receiving minimally emetogenic and moderately emetogenic chemotherapy (N = 70) were observed to be 100 % compliant. Patients receiving doxorubicin/cyclophosphamide were numerically less likely to receive institutional guidelines, compared to patients receiving other chemotherapy regimens (OR, 0.24 (0.04, 1.36), p value, 0.05). The nurse survey suggested significant variability amongst the involved institutions with regards to antiemetic prescribing practices.
CONCLUSIONS: Computerized physician order entry is associated with impressive adherence to clinician-prescribing practices, according to institutional guidelines, for acute and delayed CINV.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24026983      PMCID: PMC3983561          DOI: 10.1007/s00520-013-1969-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  25 in total

Review 1.  Why don't physicians follow clinical practice guidelines? A framework for improvement.

Authors:  M D Cabana; C S Rand; N R Powe; A W Wu; M H Wilson; P A Abboud; H R Rubin
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

2.  Computerized provider order entry in pediatric oncology: design, implementation, and outcomes.

Authors:  Allen R Chen; Christoph U Lehmann
Journal:  J Oncol Pract       Date:  2011-07       Impact factor: 3.840

3.  Electronic Chemotherapy Order Entry: A Major Cancer Center's Implementation.

Authors:  Nancy T Sklarin; Svetlana Granovsky; Eileen M O'Reilly; Andrew D Zelenetz
Journal:  J Oncol Pract       Date:  2011-07       Impact factor: 3.840

Review 4.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

5.  Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Italian Group for Antiemetic Research.

Authors: 
Journal:  Ann Oncol       Date:  1998-07       Impact factor: 32.976

Review 6.  History of the development of antiemetic guidelines at Mayo Clinic Rochester.

Authors:  C L Loprinzi; S R Alberts; B J Christensen; L J Hanson; D R Farley; J K Broers; D L Betcher; R E Grady; P A Southorn; T M Johnson; E A Perez
Journal:  Mayo Clin Proc       Date:  2000-03       Impact factor: 7.616

Review 7.  Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.

Authors:  Tobias Engel Ayer Botrel; Otávio Augusto C Clark; Luciana Clark; Luciano Paladini; Enéas Faleiros; Bruna Pegoretti
Journal:  Support Care Cancer       Date:  2010-05-22       Impact factor: 3.603

8.  Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study.

Authors:  G Dranitsaris; P Leung; D Warr
Journal:  Support Care Cancer       Date:  2001-11       Impact factor: 3.603

9.  Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions.

Authors:  Fausto Roila
Journal:  Support Care Cancer       Date:  2004-03-25       Impact factor: 3.603

10.  Cancer patients submitted to innovative chemotherapeutic agents of intermediate emetogenic potential: antiemetic prescriptions and incidence of emesis.

Authors: 
Journal:  Tumori       Date:  2004 Jan-Feb
View more
  4 in total

Review 1.  Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting.

Authors:  Hanno Riess; Cihan Ay; Rupert Bauersachs; Cecilia Becattini; Jan Beyer-Westendorf; Francis Cajfinger; Ian Chau; Alexander T Cohen; Alok A Khorana; Anthony Maraveyas; Marcos Renni; Annie M Young
Journal:  Oncologist       Date:  2018-04-12

Review 2.  Personalization and Patient Involvement in Decision Support Systems: Current Trends.

Authors:  S Quaglini; L Sacchi; G Lanzola; N Viani
Journal:  Yearb Med Inform       Date:  2015-08-13

3.  Factors affecting the implementation of guideline-based prophylactic antiemetic therapy for chemotherapy-induced nausea and vomiting in Japan: a protocol for a hospital-based qualitative study.

Authors:  Akiko Yaguchi-Saito; Yuki Kaji; Ayumu Matsuoka; Ayako Okuyama; Maiko Fujimori; Junko Saito; Miyuki Odawara; Aki Otsuki; Yosuke Uchitomi; Sadamoto Zenda; Taichi Shimazu
Journal:  BMJ Open       Date:  2022-06-06       Impact factor: 3.006

4.  What occurs in the other 20% of cancer patients with chemotherapy-induced nausea and vomiting (CINV)? A single-institution qualitative study.

Authors:  Daniel S Childs; Sherry Looker; Jennifer Le-Rademacher; Jennifer L Ridgeway; Carmen Radecki Breitkopf; Aminah Jatoi
Journal:  Support Care Cancer       Date:  2018-06-25       Impact factor: 3.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.